Iambic prices its IPO, seeking to raise up to $160m
AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Matchpoint scores $150m for I&I drugs, and other financings
Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.
argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Viatris builds in pain relief with $1.65bn Pacira purchase
As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira BioSciences.
Pfizer's Tukysa greenlit for earlier use in breast cancer
Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event
3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights
CPHI Milan 2026 showcases new Sustainability Summit
The first-time event will bring delegates together to discuss sustainability challenges